Learn about April 2025’s top biotech deals, featuring major collaborations in bispecific antibodies, protein therapies, and ...

Merck KGaA led the way in pharmaceutical M&A in April. The German company announced a $3.9 billion deal to buy the US drug ...

Ionis Pharmaceuticals unveiled results from a survey conducted by The Harris Poll showing that 91% of surveyed adults living ...

We recently published a list of the Best Income Stocks to Invest in Now. In this article, we are going to take a look at ...

Merck KGaA to buy Springworks for $3.9 billion Merck KGaA (OTCPK:MKGAF) is set to acquire SpringWorks Therapeutics (SWTX) for ...

Merck KGaA has reached an agreement with SpringWorks on a $47-per-share ... coming after it paid Chinese biotech Abbisko Therapeutics $70 million upfront for rights to pimicotinib, a drug in ...

While Merck's earnings were... SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) shares are trading higher on Monday after the company inked a deal to be acquired by Merck & Company, Inc. (NYSE ...

The German pharmaceutical company Merck KGaA is negotiating the acquisition of the American manufacturer of drugs for the treatment of cancer and rare diseases SpringWorks Therapeutics Inc. This is ...

In the vehicles’ strongest showing since early 2022, there were eight new SPACs from April 28 through May 5. Of those eight, ...

Germany's Merck KGaA in $3.9 billion deal to buy US biotech firm SpringWorks Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Eli Lilly & Co (LLY – Research Report), Moderna (MRNA – Research Report) and Envista Holdings ...

Experts say market turmoil has made it harder for buyers and sellers to agree on price, which can be an especially imposing ...